Ovarian Cancer Uk

Ovarian Cancer - Analysis of pipeline drugs and Forecasts to 2016

Summary

Specialist in Industry Analysis, released a new report, "Ovarian Cancer - New Drug Pipeline Analysis and Forecasts to 2016". The report is an essential source of information and analysis on the global market for ovarian cancer. The report identifies key trends shaping and driving the market worldwide for ovarian cancer. The report also gives an overview of the prevailing competitive landscape and emerging players should lead to changes significant position in the market for existing market leaders. More importantly, the report provides valuable information on products in the pipeline industry ovarian cancer worldwide.

This report is built using data and information from proprietary databases, primary research, secondary and internal analysis by the team of industry experts. Estimated global market for ovarian cancer should be assessed at 697 million dollars in 2009. It is expected to grow 13.1% annually for the next seven years to reach 1,650 million dollars by 2016. This growth is primarily due to rate limitation of existing chemotherapy, pipeline and solid promotion of new targeted therapies. Analyzed the global market for ovarian cancer is moderately used with product options and range significantly to the provision of new entrants that would capture the value of underserved segments. Design products cured with high efficiency and safety profile is one of the main challenges of this market and could provide significant market share for any company. analyzed the global market for ovarian cancer is increasingly becoming more competitive. Balancing the pipeline with current products on the market and expectations of patients and physicians, the pipeline is considered strong. The unmet need in the market for ovarian cancer is high and if a company wants to capture this unmet need, it will need to overcome the weaknesses of the current product and adverse events.

Scope

The scope of this report includes:

• Global annualized ovarian cancer market income data from 2001 to 2009, forecasts for 7 years before 2016.

• Geographies covered in this report include the United States, the United Kingdom, Italy, Spain, Germany, France and Japan.

• data analysis pipeline providing a split between the different phases, the mechanism of action in development and new trends. Classes key mechanism of action includes the topoisomerase inhibitor, drugs targeting DNA vaccines, drugs that target growth factor receptors and growth factor receptor binding of folic acid, kinase inhibitor, drugs targeting cytokines and treatment combinations.

• Analysis of competition in existing markets and future global market for ovarian cancer. key market players covered are F. Hoffmann-La Roche Ltd v Genentech, Inc., Menarini Group, Novartis AG, Cell Therapeutics Inc., Telik, Inc. BioNumerik Pharmaceuticals Inc.

• comprehensive review of Key industry drivers, constraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

• Key topics covered include assessing strategic competitor, the characterization of the market, unmet needs and the implications for the futures market associated with ovarian cancer.

For more information, please visit:

http://www.aarkstore.com/reports/Ovarian-Cancer-Drug-Pipeline-Analysis-and.